{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-117947","form_type":"8-K","ticker":"CAPR","cik":"0001133869","company_name":"CAPRICOR THERAPEUTICS, INC.","filed_at":"2025-12-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.868405+00:00","generated_at":"2026-05-16T15:01:46.014955+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Capricor Therapeutics Announces Positive Phase 3 HOPE-3 Results for Deramiocel in Duchenne Muscular Dystrophy","bullets":["Primary endpoint PUL v2.0 met with 54% slowing of progression (p=0.029) in 105 evaluable patients.","Key secondary cardiac endpoint LVEF showed 91% slowing of decline (p=0.041) in 83 evaluable patients.","Study enrolled 106 participants (average age 15) across 20 U.S. sites; over 75% had diagnosed cardiomyopathy.","Deramiocel maintained a favorable safety and tolerability profile consistent with prior clinical experience.","Company plans to submit response to Complete Response Letter incorporating HOPE-3 data following prior FDA alignment."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-117947","json":"https://secwatch.observer/filing/0001104659-25-117947.json","markdown":"https://secwatch.observer/filing/0001104659-25-117947.md","text":"https://secwatch.observer/filing/0001104659-25-117947.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133869/000110465925117947/0001104659-25-117947-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133869/000110465925117947/capr-20251203x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-16T15:01:46.014955+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}